Stefan Proniuk

495 total citations
23 papers, 392 citations indexed

About

Stefan Proniuk is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Pharmaceutical Science. According to data from OpenAlex, Stefan Proniuk has authored 23 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Pharmaceutical Science. Recurrent topics in Stefan Proniuk's work include Drug Solubulity and Delivery Systems (3 papers), Estrogen and related hormone effects (3 papers) and Prostate Cancer Treatment and Research (3 papers). Stefan Proniuk is often cited by papers focused on Drug Solubulity and Delivery Systems (3 papers), Estrogen and related hormone effects (3 papers) and Prostate Cancer Treatment and Research (3 papers). Stefan Proniuk collaborates with scholars based in United States, United Kingdom and Australia. Stefan Proniuk's co-authors include James Blanchard, Bianca M. Liederer, Alexander Zukiwski, Robert J. Noecker, Heath Ecroyd, Jane L. Roberts, Paul Dent, Laurence Booth, Juliette Blanchard and S. Narasimha Murthy and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Stefan Proniuk

22 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan Proniuk United States 13 101 85 73 49 49 23 392
Eman Sheta Egypt 13 167 1.7× 51 0.6× 37 0.5× 18 0.4× 21 0.4× 58 467
Jo Linda Sinagra Italy 12 86 0.9× 57 0.7× 57 0.8× 115 2.3× 15 0.3× 21 763
Ehssan Moglad Saudi Arabia 15 262 2.6× 47 0.6× 45 0.6× 12 0.2× 20 0.4× 86 585
Yongmei Hao China 6 127 1.3× 238 2.8× 43 0.6× 17 0.3× 37 0.8× 13 446
P. Gilchrist United Kingdom 8 125 1.2× 84 1.0× 52 0.7× 6 0.1× 56 1.1× 10 344
Hao Ran China 11 104 1.0× 122 1.4× 27 0.4× 10 0.2× 29 0.6× 45 494
Dinesh G. Goswami United States 14 162 1.6× 32 0.4× 33 0.5× 11 0.2× 55 1.1× 36 471
Chooi Ling Lim Malaysia 12 210 2.1× 85 1.0× 36 0.5× 16 0.3× 19 0.4× 28 496
A. I. Mallet United Kingdom 14 188 1.9× 15 0.2× 43 0.6× 20 0.4× 15 0.3× 31 644
Vicente Nogués Switzerland 5 133 1.3× 36 0.4× 14 0.2× 13 0.3× 27 0.6× 7 469

Countries citing papers authored by Stefan Proniuk

Since Specialization
Citations

This map shows the geographic impact of Stefan Proniuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Proniuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Proniuk more than expected).

Fields of papers citing papers by Stefan Proniuk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Proniuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Proniuk. The network helps show where Stefan Proniuk may publish in the future.

Co-authorship network of co-authors of Stefan Proniuk

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Proniuk. A scholar is included among the top collaborators of Stefan Proniuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Proniuk. Stefan Proniuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xie, Hao, Anthony B. El-Khoueiry, Angela Alistar, et al.. (2024). A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).. Journal of Clinical Oncology. 42(16_suppl). 3078–3078. 2 indexed citations
2.
3.
Cottu, Paul, Jacques Bonneterre, Andréa Varga, et al.. (2018). Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE. 13(10). e0204973–e0204973. 24 indexed citations
4.
5.
Hassandarvish, Pouya, Adrian Oo, Alexander Zukiwski, et al.. (2017). Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes. Journal of Antimicrobial Chemotherapy. 72(9). 2438–2442. 7 indexed citations
6.
Shivakumar, H.N., et al.. (2017). Trans-ungual Delivery of AR-12, a Novel Antifungal Drug. AAPS PharmSciTech. 18(7). 2702–2705. 18 indexed citations
7.
Abdulrahman, Basant, Dalia H. Abdelaziz, Simrika Thapa, et al.. (2017). The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. Scientific Reports. 7(1). 17565–17565. 25 indexed citations
8.
Booth, Laurence, Jane L. Roberts, Heath Ecroyd, et al.. (2016). AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology. 231(10). 2286–2302. 33 indexed citations
9.
Booth, Laurence, Jane L. Roberts, Heath Ecroyd, et al.. (2016). AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins. Journal of Clinical & Cellular Immunology. 7(5). 6 indexed citations
10.
11.
Mateo, Joaquı́n, Daniel Nava Rodrigues, Penelope Flohr, et al.. (2014). A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 32(15_suppl). TPS5097–TPS5097. 2 indexed citations
12.
Mateo, Joaquı́n, Johann S. de Bono, Ramesh K. Ramanathan, et al.. (2013). A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2608–2608. 14 indexed citations
13.
Proniuk, Stefan, et al.. (2002). Topical Formulation Studies with DEET (N,N‐Diethyl‐3‐methylbenzamide) and Cyclodextrins. Journal of Pharmaceutical Sciences. 91(1). 101–110. 16 indexed citations
14.
Proniuk, Stefan, Bianca M. Liederer, & James Blanchard. (2002). Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention. Journal of Pharmaceutical Sciences. 91(1). 111–116. 62 indexed citations
15.
Proniuk, Stefan & James Blanchard. (2002). Anhydrous Carbopol® Polymer Gels for the Topical Delivery of Oxygen/Water Sensitive Compounds. Pharmaceutical Development and Technology. 7(2). 249–255. 24 indexed citations
16.
Proniuk, Stefan & James Blanchard. (2001). Influence of degree of substitution of cyclodextrins on their colligative properties in solution. Journal of Pharmaceutical Sciences. 90(8). 1086–1090. 17 indexed citations
17.
Proniuk, Stefan, et al.. (2001). Effect of Temperature and Light on the Stability of Latanoprost and its Clinical Relevance. Journal of Glaucoma. 10(5). 401–405. 38 indexed citations
18.
Proniuk, Stefan, et al.. (2001). Investigation of the Utility of an In Vitro Release Test for Optimizing Semisolid Dosage Forms. Pharmaceutical Development and Technology. 6(3). 469–476. 18 indexed citations
19.
Blanchard, James & Stefan Proniuk. (1999). Some Important Considerations in the Use of Cyclodextrins. Pharmaceutical Research. 16(12). 1796–1798. 29 indexed citations
20.
Proniuk, Stefan, et al.. (1998). A Simplified and Rapid High-Performance Liquid Chromatographic Assay for Ketoprofen in Isopropyl Myristate. Journal of Chromatographic Science. 36(10). 495–498. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eman Sheta Breakdown of academic impact, for papers by Jo Linda Sinagra Breakdown of academic impact, for papers by Ehssan Moglad Breakdown of academic impact, for papers by Yongmei Hao Breakdown of academic impact, for papers by P. Gilchrist Breakdown of academic impact, for papers by Hao Ran Breakdown of academic impact, for papers by Dinesh G. Goswami Breakdown of academic impact, for papers by Chooi Ling Lim Breakdown of academic impact, for papers by A. I. Mallet Breakdown of academic impact, for papers by Vicente Nogués
Rankless by CCL
2026